Related Experiment Videos
[Hyperlipidemia in patients over 60 years old]
E Bruckert1, F Delahaye, J L Richard
1Service d'endocrinologie métabolisme, hôpital Pitié-Salpêtrière, Lyon.
Insights
Managing hyperlipidemia in older adults (60+) presents challenges due to metabolic issues. Treatment decisions require careful consideration of risks and benefits, often extrapolating from younger populations.
Area of Science:
- Gerontology
- Cardiovascular Medicine
- Metabolic Disorders
Context:
- Hyperlipidemia management in individuals aged 60 and over is complex.
- Cardiovascular disease prevalence and risk factors like hypertension and smoking significantly increase with age.
- Serum cholesterol levels generally rise with age, though the mechanisms are not fully understood.
Purpose:
- To address the challenges in managing hyperlipidemia in the elderly.
- To evaluate the uncertainties surrounding cholesterol-lowering treatments in individuals over 60.
- To provide practical clinical advice based on existing data and reasoned extrapolation.
Summary:
- Hypercholesterolemia is a risk factor in the elderly, with absolute risk increasing despite decreasing relative risk with age.
- No specific therapeutic trials exist for lowering serum cholesterol in those over 60.
- Treatment decisions should consider life expectancy and be reserved for severe hyperlipidemia cases.
Impact:
- Highlights the need for cautious application of international recommendations in older adults.
- Suggests a pragmatic approach to hyperlipidemia management in the elderly, prioritizing severe cases.
- Emphasizes the importance of individualized treatment strategies based on life expectancy and risk assessment.
Abstract:
The management of hyperlipidemia in individuals aged 60 or over is a serious problem, given the frequency of metabolic abnormalities in this age group. The decision to treat must take into account a number of uncertainties. Hypercholesterolemia is a risk factor in the elderly and, in general, its importance varies like the other major risk factors (hypertension and smoking): the relative risk decreases with age but this decrease in relative risk is associated with an increase in the absolute risk because the prevalence of cardiovascular disease greatly increases with age. The serum cholesterol level increases with age but the physiopathological mechanism os this increase is poorly understood (reduction in the number of LDC receptors?). In the over 70s, serum cholesterol levels decrease, probably because of a selection due to the deaths of subjects at higher risk. No therapeutic trials have been performed to evaluate the effects of lowering the serum cholesterol in the over 60s. In addition, strict application of international recommendations in this age group would result in a large number of therapeutic interventions, the value of which would be questionable. Under these conditions, practical clinical advice is based on reasoned extrapolation of epidemiological data obtained in middle-aged men. Treatment should therefore be reserved for sever forms of hyperlipidemia, taking into consideration the life expectancy of the individual.